Dr. Reddys Laboratories through its subsidiary Promius Pharma has received USFDA approval to market Sernivo spray, used in treatment of skin disorder. The drug Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The company will have the commercial launch of the product in Apr-June 2016. Promius has conducted two multi-center, randomised, double-blind, vehicle-controlled clinical trials in subjects aged 18 years and older with moderate plaque psoriasis to evaluate the safety and efficacy of Sernivo Spray.
Company Profile : Dr Reddys Laboratories Ltd